Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $67 from $50 and keeps an Outperform rating on the shares. The firm, which applies a new probability-of-success framework to Ultragenyx’s GTX-102 Phase 3 Angelman readout expected in the second half of 2026, sees “a favorable asymmetric setup” with 50%-70% upside potentia. versus about 20% downside on failure, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
- Ultragenyx BLA for UX111 Accepted for FDA Review
- Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
- Ultragenyx Wins FDA IND Clearance for UX016 Therapy
- Ultragenyx announces FDA clearance of UX016 investigational new drug application